Wide Ranks

EOLS

Evolus, Inc. Common Stock

13.80

Top Statistics
Market Cap 873 M Forward PE 219.05 Revenue Growth 22.10 %
Current Ratio 2.47 Trailing PE 0.0000 Earnings Growth 0.00 %
Profit Margins -22.33 % Peg Ratio Dividend Yield 0.00 %
Enterprice / EBITA -34.97 Enterprise / Revenue 3.70 Price To Sales Trailing12 Months 3.52
Profitability
Profit Margins -22.33 % Operating Margins -21.36 %
Balance Sheet
Total Cash 85 M Total Cash Per Share 1.34 Total Debt 129 M
Total Debt To Equity 2205.01 Current Ratio 2.47 Book Value Per Share 0.0930
All Measures
Short Ratio 804.00 % Message Board Id finmb_229087176 Shares Short Prior Month 4 M
City Newport Beach Uuid 90cb1fd6-b636-380b-949e-bd8942fd419e Previous Close 12.83
First Trade Date Epoch Utc 1 B Book Value 0.0930 Beta 1.31
Total Debt 129 M Volume 802514 Price To Book 148.39
Fifty Two Week Low 9.34 Total Cash Per Share 1.34 Total Revenue 248 M
Shares Short Previous Month Date 1 B Target Median Price 25.00 Max Age 86400
Recommendation Mean 1.57 Sand P52 Week Change 0.3133 Operating Margins -21.36 %
Target Mean Price 23.43 Net Income To Common -55460000 Short Percent Of Float 0.0853
Implied Shares Outstanding 63 M Trailing Peg Ratio None Last Fiscal Year End 1 B
Average Daily Volume10 Day 694350 Average Volume10days 694350 Total Cash 85 M
Next Fiscal Year End 1 B Revenue Per Share 4.11 Held Percent Insiders 0.1231
Ebitda Margins -10.58 % Trailing PE 0.0000 Date Short Interest 1 B
Most Recent Quarter 1 B Regular Market Previous Close 12.83 Target Low Price 20.00
Gmt Off Set Milliseconds -18000000 Fifty Day Average 15.37 Open 12.93
Free Cashflow -7398125 State CA Dividend Yield 0.00 %
Return On Assets -0.0993 Time Zone Short Name EST Trailing Eps -0.9100
Day Low 12.83 Address1 520 Newport Center Drive Shares Outstanding 63 M
Price Hint 2 Target High Price 27.00 Website https://www.evolus.com
52 Week Change 0.4572 Average Volume 638453 Forward Eps 0.2000
Recommendation Key buy Compensation As Of Epoch Date 1 B Quick Ratio 213.20 %
Is_sp_500 False Regular Market Day High 13.84 Profit Margins -22.33 %
Debt To Equity 2205.01 Fifty Two Week High 17.82 Day High 13.84
Shares Short 5 M Regular Market Open 12.93 Industry Key drug-manufacturers-specialty-generic
Earnings Growth 0.00 % Enterprise To Revenue 3.70 Revenue Growth 22.10 %
Shares Percent Shares Out 0.0835 Operating Cashflow -21994000 Currency USD
Time Zone Full Name America/New_York Market Cap 873 M Is_nasdaq_100 False
Zip 92660 Quote Type EQUITY Industry Drug Manufacturers - Specialty & Generic
Long Name Evolus, Inc. Regular Market Day Low 12.83 Held Percent Institutions 0.8020
Current Price 13.80 Address2 Suite 1200 Enterprise To Ebitda -34.97
Financial Currency USD Current Ratio 2.47 Gross Margins 69.94 %
Industry Disp Drug Manufacturers - Specialty & Generic Number Of Analyst Opinions 7 Country United States
Float Shares 49 M Two Hundred Day Average 13.72 Enterprise Value 918 M
Price To Sales Trailing12 Months 3.52 Forward PE 219.05 Regular Market Volume 802514
Ebitda -26272000 Exchange NGM
Go to Yahoo Finance Go to Seeking Alpha 
Evolus, Inc., a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe.

The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults; and Nuceiva, for the temporary improvement in the appearance of moderate to severe vertical lines between the eyebrows seen at maximum frown.

It also provides dermal filler products under the Estyme and Evolysse names.

The company was incorporated in 2012 and is headquartered in Newport Beach, California.